ストックスクリーナーアプリを入手
7.78
2.37%
0.18
プレマーケット:
7.76
-0.02
-0.26%
前日終値:
$7.60
開ける：
$7.54
24時間の取引高:
10.41M
Relative Volume:
0.28
時価総額：
$8.03B
収益：
$113.29M
当期純損益:
$-351.47M
株価収益率:
-19.96
EPS:
-0.3898
ネットキャッシュフロー:
$-309.19M
1週間 パフォーマンス:
+11.46%
1か月 パフォーマンス:
-7.27%
6か月 パフォーマンス:
+201.55%
1年 パフォーマンス:
+179.86%
1日の値動き範囲:
$7.36
$7.805
1週間の範囲:
$6.97
$7.82
52週間の値動き範囲:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.78 | 7.85B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-05-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
すべてを表示
Immunitybio Inc (IBRX) 最新ニュース
Robbins LLP Urges IBRX Stockholders Who Lost Money Investing in ImmunityBio, Inc. to Contact the Firm for Information About Leading the Class Action - Morningstar
REMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026 - GlobeNewswire
ImmunityBio Inc stock (US45258J1025): Is its immunotherapy pipeline strong enough to unlock biotech - AD HOC NEWS
INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class ActionHagens Berman - Morningstar
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
ImmunityBio Faces Securities Fraud Lawsuit - National Today
ImmunityBio, Inc. (IBRX) Securities Fraud: Contact Berger Montague To Discuss Your Rights - marketscreener.com
IBRX Investor Alert: ImmunityBio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Violated FDA Drug Rules: Levi & Korsinsky - PR Newswire
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - GlobeNewswire Inc.
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Lawsuit Alert: Investors who lost money with shares - openPR.com
ImmunityBio, Inc. Class Action Lawsuit: Investors Face May 26, 2026, Deadline - The Globe and Mail
IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline - marketscreener.com
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C. - Toronto Star
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
ImmunityBio founder pushes back after FDA warning letter over Anktiva claims — says ad never aired at all - MSN
ImmunityBio Founder Disputes FDA Warning Over Anktiva Claims - National Today
IBRX stock set to snap 2 days of losses? Anktiva back in focus ahead of COVID-cancer link data - MSN
ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman - PR Newswire
ZSPC Investor News: If You Have Suffered Losses in zSpace Inc. (NASDAQ: ZSPC), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel ... - Caledonian Record
Lowey Dannenberg Notifies ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) ... - Caledonian Record
Lowey Dannenberg Notifies ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm - GlobeNewswire
Kaplan Fox Reminds ImmunityBio, Inc. (NASDAQ: IBRX) Investors of - The National Law Review
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm - Sahm
ImmunityBio, Inc. (IBRX) Posts Strong Preliminary Q1 Sales on ANKTIVA Momentum - Yahoo Finance
Wall Street Bullish on ImmunityBio (IBRX) Since the Announcement of New Findings From QUILT-3.055 Study - MSN
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - GlobeNewswire Inc.
IBRX Investors Eligible to Lead Fraud Lawsuit - National Today
IBRX Stock Set To Snap 2 Days Of Losses? Anktiva Back In Focus Ahead Of COVID-Cancer Link Data - Stocktwits
IBRX Stock In Spotlight: ImmunityBio Guides For 168% Revenue Surge In Q1 On ANKTIVA Momentum - Stocktwits
Press releases provided by CNW - Techaeris
New ImmunityBio timeline emerges - observertoday.com
Investors with Substantial Losses Have Opportunity to Lead ImmunityBio Class Action Lawsuit - National Today
Robbins Geller Announces ImmunityBio Investor Lawsuit Deadline - National Today
IBRX SEC FilingsImmunitybio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with - GlobeNewswire
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - NewMediaWire
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results - Yahoo Finance
IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Business Wire
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
IBRX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ImmunityBio, ... - Bluefield Daily Telegraph
IBRX Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
NK Cell Therapy Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Amgen, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Artiva Biotherap - Barchart.com
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):